Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Co. to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. Co. integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. The RXRX stock yearly return is shown above.
The yearly return on the RXRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2024 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RXRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|